A model for success
We are led by a team of passionate and respected experts with proven track records of success in drug discovery and commercialization. Their knowledge and experience help foster and inspire innovation at every level of the company. Learn more about what makes us unique.
Our Board of Directors includes the executive leadership of Sumitomo Dainippon Pharma Co., Ltd.
Patricia S. Andrews
Chief Executive Officer
Global Head of Oncology
Patricia S. Andrews serves as the Chief Executive Officer and Global Head of Oncology. Prior to joining Sumitomo Dainippon Pharma Oncology (SDP Oncology), Ms. Andrews spent seven years at Boston Biomedical, Inc., one of the predecessor companies, and served as Chief Executive Officer and Chief Operating Officer.
Prior to joining Boston Biomedical, Ms. Andrews served as Executive Vice President and Chief Commercial Officer at Incyte Corporation, a U.S.-based biopharmaceutical company. In this role, she led the transition from a clinical-stage research and development organization to a successful commercial enterprise with the launch of its first-for-the-company, first-in-class, first-in-disease, orphan oncology product. She established the commercial organization and led all functions within sales and marketing. She was also responsible for business development and completed multiple significant product licensing deals for Incyte, including one of the largest licensing deals in biotech in 2009.
Prior to her experience at Incyte, Ms. Andrews spent 17 years at Pfizer Inc., culminating in her role as Vice President and General Manager of the U.S. Oncology Business Unit, at the time a $900 million portfolio of products in colorectal cancer, breast cancer, and renal cell carcinoma. Ms. Andrews is an Executive Officer of Sumitomo Dainippon Pharma Co., Ltd. and serves on the board of GlycoMimetics [Nasdaq: GLYC]. Ms. Andrews received her MBA from the University of Michigan and a BA from Brown University.
David J. Bearss, Ph.D.
Chief Scientific Officer
Global Head of Research
David J. Bearss, Ph.D. serves as the Chief Scientific Officer and Global Head of Research. Prior to joining SDP Oncology, Dr. Bearss founded Tolero Pharmaceuticals, Inc., one of the predecessor companies, and served as Chief Executive Officer.
Dr. Bearss has established a consistent and successful track record of drug discovery and development that spanned the last 20 years in both academic and industrial settings. Dr. Bearss is an expert in small-molecule drug development and in the use of genetic model systems in drug discovery. He has deep experience in translational research focused on drug development and the use of genetic and functional markers to predict drug sensitivity. He is also an expert in the development and use of genetically modified animals to model human disease. Dr. Bearss received his Ph.D. in Cell and Structural Biology at the University of Texas Health Sciences Center at San Antonio and was a postdoctoral fellow with Dr. Daniel Von Hoff, a recognized leader in oncology drug development. Dr. Bearss was on the faculty of the University of Arizona from 1999 to 2003, after which he co-founded Montigen Pharmaceuticals, where he served as Chief Scientific Officer until Montigen was acquired by SuperGen in 2006. Dr. Bearss served as Chief Scientific Officer at SuperGen, overseeing early drug discovery and development, and was subsequently co-director of the Center for Investigational Therapeutics at the Huntsman Cancer Institute, where he was an Associate Professor in the Department of Oncological Sciences at the University of Utah. Dr. Bearss was also an Associate Professor of Physiology & Developmental Biology at Brigham Young University. Dr. Bearss has published more than 70 manuscripts and book chapters, is an author on over 150 abstracts presented at international meetings, and has more than 50 patents issued or pending. Dr. Bearss has also won several awards for his scientific and entrepreneurial achievements.
Edgar Braendle, M.D., Ph.D.
Chief Medical Officer
Global Head of Development
Edgar Braendle, M.D., Ph.D. serves as the Chief Medical Officer and Global Head of Development. Prior to joining SDP Oncology, Dr. Braendle spent three years at Boston Biomedical, Inc., one of the predecessor companies, and served as Executive Vice President, Head of R&D and Chief Medical Officer.
Dr. Braendle has more than 20 years of industry experience leading clinical development and oncology diagnostics and treatments. Prior to joining Boston Biomedical, he served as President and CEO of ARUP Laboratories, a national clinical and anatomic pathology reference laboratory. Previously, he spent more than a decade at Novartis Pharmaceutical Corporation, culminating in his role as Senior Vice President and Global Head of Companion Diagnostics. In this role, Dr. Braendle led the company’s precision medicine approach, delivering all complementary and companion diagnostics for Novartis medicines, and driving exploratory biomarker development. In an earlier position as Vice President, Global Head of Oncology Biologics, he developed Novartis oncology biologics in early to late stages, successfully filing eight investigational new drug applications.
Dr. Braendle received a medical degree and training in hematologic malignancies and solid tumor oncology, pharmacology and urology at the University of Aachen, University of Bonn, and the University of Ulm in Germany.
Senior Vice President
Chief Commercial Officer
Dee Mahoney serves as Senior Vice President, Chief Commercial Officer. In this role, she leads the commercialization of oncology assets originating from the company. In addition to commercialization, Ms. Mahoney plays a leadership role in new product planning and external innovation for oncology across all regions.
Ms. Mahoney’s 30 years of experience in the biopharmaceutical industry focused on roles ranging from field sales to executive leadership. Prior to joining the company, she was co-founder and President of DMH BioPharm Advisors, a management-consulting firm. In this role, Ms. Mahoney partnered with biopharmaceutical companies to maximize the effectiveness of commercial strategies and reduce the risk of regulatory noncompliance.
Before that, Ms. Mahoney spent 20 years at Pfizer Inc., culminating in the role of Senior Vice President and General Manager of Pfizer’s U.S. Specialty Products Business Unit, where she was responsible for the $2.5 billion specialty business unit comprised of oncology, anti-infective, HIV, ophthalmology, and endocrine-care products.
Ms. Mahoney received her Bachelor of Science degree in Microbiology and Organic Chemistry from Stephen F. Austin State University.
Masashi Murata, Ph.D.
Chief Strategy Officer
Global Strategy and Planning
Masashi Murata, Ph.D. serves as Chief Strategy Officer, Global Strategy and Planning. In this role, he formulates and monitors the execution of corporate strategy and associated plans in support of the company’s vision, mission, and business imperatives. Prior to joining SDP Oncology, Dr. Murata served as Chief Strategic Officer, Global Strategy and Planning and Vice President of Corporate Strategy and Planning at Boston Biomedical, Inc., one of the predecessor companies.
Dr. Murata has more than 26 years of experience in the biopharmaceutical industry, leading multiple clinical development programs in Japan and managing collaborations and alliances. Dr. Murata also oversaw clinical development programs, drug discovery and preclinical research programs at Sumitomo Dainippon Pharma Co., Ltd., culminating in the role of Director in the Global Strategy Group of the Global Oncology Office. Dr. Murata also led several preclinical-stage research programs, including in-house at Sumitomo Dainippon Pharma and third-party collaboration programs at AstraZeneca plc in immunology, gene therapy, and oncology.
Dr. Murata earned his Doctor of Philosophy and Faculty of Sciences degrees from Kyoto University in Kyoto, Japan, and has also co-authored articles in several peer-reviewed publications.
Senior Vice President
Chief Financial Officer
Mark Westgate serves as the Senior Vice President, Chief Financial Officer. In this role, he manages all financial planning as well as monthly, quarterly, and annual reporting and ensures all accounting activities comply with financial regulations.
With over 20 years of experience in life sciences and biotechnology, Mr. Westgate has managed finances for several companies over the course of his career. Prior to joining the company, he served as the Chief Financial Officer at Hitachi Chemical Advanced Therapeutics Solutions, L.L.C., (formerly PCT Cell Therapy Services, L.L.C.), where he managed all aspects of financial reporting, internal controls, S.E.C. and regulatory filings, tax, treasury and other financial operations. Previously, he served as the Chief Financial Officer, Treasurer, and Assistant Secretary at Apricus Biosciences, Inc. (formerly NexMed, Inc.) and prior to that, he was Group Controller and Treasurer at Lavipharm Corp. He also currently serves on the Board of Directors of Thermogenesis Holdings, Inc. (NASDAQ: THMO) and is Chairman of the Audit Committee.
Mr. Westgate is a Certified Public Accountant and earned a Bachelor of Business Administration degree in Public Accounting from Pace University.